title: Migraine and tension-type headache reduction through pericranial muscular suppression: a preliminary report.
abstract: Migraine and tension-type headaches have always plagued mankind. In spite of all the research dollars spent trying to determine the etiologies of these headaches, the neurology community still has not established a known cause of migraine and tension type headaches. This paper describes a study that was conducted for the U.S. Food and Drug Administration in which the efficacy of the Nociceptive Trigeminal Inhibition Tension Suppression System was evaluated and proved safe and efficacious in the reduction of medically diagnosed migraine and tension-type headache.
authors.affiliation: drwes@drshankland.com
authors.forename: W E
authors.initials: WE
authors.lastname: Shankland
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D003768:Dental Occlusion, Centric; D018795:Device Approval; D004867:Equipment Design; D004869:Equipment Safety; D005260:Female; D006801:Humans; D008297:Male; D008499:Medical Records; D008881:Migraine Disorders / Q000517:prevention & control*; D009433:Neural Inhibition; D009619:Nociceptors / Q000503:physiopathology; D017090:Occlusal Splints; D010147:Pain Measurement; D010919:Placebos; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D013223:Statistics as Topic; D018170:Sumatriptan / Q000627:therapeutic use; D018781:Tension-Type Headache / Q000517:prevention & control*; D014276:Trigeminal Nerve / Q000503:physiopathology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000700:Analgesics; D010919:Placebos; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan